Future HIV vaccine research should consider the balance between responses that favor protection and those that lead to susceptibility to infection.
instead of forward, a phenotype they dubbed "moonwalker." Conversely, silencing these neurons greatly inhibited backward walking in situations, such as hitting a dead end, where wild-type flies normally choose to walk backward.
By expressing green fl uorescent protein (GFP) under the control of Gal4/UAS instead of TrpA1, they found that the moonwalker line was active in seven morphologically distinct neurons. Subsequent experiments designed to identify which of the seven were important revealed that bilaterally activating only a specifi c pair of neurons was suffi cient to make fl ies "do the moonwalk." While one of these neurons was located in the brain and sent its axon posteriorly into the ventral nerve cord (VNC), where motor neuron cell bodies reside, the second neuron had the opposite orientation: Its cell body resided in a posterior region of the VNC and sent its axon anteriorly, into the brain (see the fi gure). On the basis of these two distinct orientations, the authors named these neurons MDN and MAN, for "moonwalker descending neuron" and "moonwalker ascending neuron," respectively (see the fi gure).
Bidaye et al. then used more precise genetic tools to tease out the individual contributions of MDN and MAN in the control of walking direction. Activation of MDN alone was suffi cient to induce a signifi cant amount of backward walking, while activating MAN alone was not. However, activating either MDN or MAN was sufficient to interfere with forward walking; fl ies in which either neuron was activated still walked forward, but for shorter distances. Thus, it seems that whereas MDN activity triggers a switch from forward to backward walking, MAN activity contributes to the moonwalker phenotype mainly by inhibiting forward walking (see the fi gure). MDN, with its cell body in the brain, may receive sensory cues from, for example, the eyes or antennae, that inform the fl y it is approaching a dead end. As such, MDN may be a "command neuron" analogous to command interneurons in Caenorhabditis elegans that promote backward crawling in response to touching the worm's head (12) (13) (14) .
Although the fi ndings of Bidaye et al. provide the fi rst glimpse into how fl ies, and perhaps other legged animals, control walking direction, many questions remain. For one, none of the upstream or downstream neurons that make functional connections with MDN or MAN are known. Of particular interest is whether and how MDN and MAN selectively modify only parts of the locomotor circuit to induce fl ies to change direction. In C. elegans, forward and backward crawling require distinct motor neurons that receive information from different command interneurons ( 13, 14) . To fi gure out whether something similar is happening in limbed locomotion, we need a better understanding of the circuitry that controls forward walking. Answers will no doubt come from a wide variety of approaches, including ones similar to those used by Bidaye et al., to provide cellular resolution to complex motor outputs such as walking.
T he development of a safe and effective HIV vaccine is perhaps the most important and challenging goal remaining in HIV-AIDS research. Recent progress using a poxvirus vector prime and envelope protein boost strategy demonstrated a modest but statistically signifi cant level of effi cacy and established the concept that a vaccine could prevent HIV infection ( 1) , and approaches to boost durability and effi cacy are currently in the planning stages ( 2) . But the results of two vaccine concepts based on recombinant adenovirus serotype-5 (rAd5) (3) (4) (5) pointed to a potential major problem-that such vaccines might increase susceptibility to HIV infection. This also raised the question of whether the problem extends to some or all of the other recombinant adenovirus vectors currently in development or to other vector-based vaccines.
Last year, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened the Mini-Summit on Adenovirus Platforms for HIV Vaccines ( 6) to investigate this issue. Furthermore, the question was raised whether increased susceptibility might be seen with any HIV vaccine that activates the immune system rendering activated CD4 + T cells more susceptible to HIV infection, while at the same time inducing little or no protective effect against HIV acquisition ( 6) .
Between 2005 and 2013, two rAd5 vaccines for HIV were assessed in three efficacy studies (3) (4) (5) . The fi rst study (Step), using three doses of the Merck rAd5 vaccine containing genes encoding three HIV-1 proteins (gag, pol, and nef), was stopped for futility. In addition, a statistically signifi cant trend toward increased HIV infections in vaccine recipients was observed ( 3, 7) . The group at highest risk was uncircumcised men who both had sex with men (MSM) and had high titers of preexisting antibodies against Ad5. The following Phambili trial of the same Merck rAd5 vaccine, conducted PERSPECTIVES in South Africa, was closed and unblinded early during the enrollment period. Few participants received the planned three doses of vaccine. Analysis of the data showed no increased risk of HIV infection ( 5) . However, data from the long-term unblinded follow-up of Phambili participants suggested an increased risk of infection in vaccinated men relative to unvaccinated controls ( 8) .
In 2009, a different rAd5 vaccine was tested in the HIV Vaccine Trial Network (HVTN) 505 trial. It contained three doses of a DNA prime (a plasmid of non-HIV DNA and certain HIV genes) followed by a single boost of rAd5 expressing HIV envelope and viral structural antigens. The study restricted enrollment to circumcised MSM who lacked preexisting antibodies to Ad5, because no level of increased risk had been seen in this group in the Step trial ( 7) . The HVTN 505 trial was halted prematurely because it met futility criteria; however, there was no evidence of increased risk of HIV infection in the vaccinated subjects ( 9) .
Results of a Meta-Analysis
A meta-analysis of the Step, Phambili, and HVTN 505 trials was performed by statisticians from the HVTN Statistics and Data Management Center and from NIAID. Combining data from the three studies, there was an overall hazard ratio of 1.33 (P < 0.01) associated with vaccination. However, almost all of the increased risk of HIV acquisition was driven by the Merck vaccine (Step and Phambili: hazard ratio = 1.41, P = 0.005) with the Step trial contributing most infection endpoints. HVTN 505 considered alone did not show any trend toward infection risk ( 6, 10) . It could not be determined whether the lack of increased susceptibility in the latter trial was due to population or regimen (inclusion of env, DNA prime, and single rAd5 boost with differences in vector backbone).
Other Ad-Based Vaccines
Alternative Ad vectors for use in tuberculosis or malaria vaccines have not been evaluated in trials in suffi cient numbers of adults at risk for HIV infection to provide useful information about possible interactions with HIV. However, active-duty U.S. Army recruits have been vaccinated with Ad4/7 to prevent highly contagious respiratory illnesses in close quarters during training ( 11) . From 1999 to 2011, the Army interrupted and then resumed vaccination with Ad4/7, creating three separate cohorts for comparison. The serologic data were reviewed retrospectively for these three cohorts, and no changes in HIV incidence were detected ( 6).
Potential Mechanisms for rAd5 Effects
In 2008, NIAID held an HIV Vaccine Summit, which fostered studies to understand the possible mechanisms of the effects seen in the Step study ( 12) . Results revealed at the 2013 NIAID Mini-Summit included those from nonhuman primate studies of the Merck rAd5-gag/pol/nef vaccine constructs. The data showed an increase in activated CD4 + T cells in the gastrointestinal mucosa after rAd vaccination and increased simian immunodefi ciency virus (SIV) acquisition after rAd-SIV vaccination; the empty rAd vector did not increase SIV acquisition ( 13) . Human gut biopsies of individuals vaccinated with the DNA prime and rAd5 boost as part of HVTN 204 (low risk) and HVTN 505 (high risk) revealed high numbers of activated Adspecifi c CD4 + T cells, with increased expression of C-C chemokine receptor type 5 (the co-receptor for HIV), but no HIV-specific cells in multiple samples from the rectum and colon ( 6) . Furthermore, the activated T cells were concentrated in unevenly distributed foci, making extensive sampling a necessity ( 14) . Although there is no current evidence of increased risk of HIV acquisition for other Ad vectors, the presence of rAd5-activated T cells in tissue and the degree of shared epitopes between Ad serotypes that are recognized by CD4 + T cells should be considered as a possible area of concern.
Ad serotype cross-reactivity can be attributed, in part, to recognition by CD4 + T cells and CD8 + T cells of highly conserved regions in Ad hexon protein across most human and primate Ad species (15) (16) (17) . Therefore, this issue must at least be considered in the riskbenefit analysis of potential HIV vaccine trials using alternate Ad vectors. However, in a phase 1 study using a single rAd26-HIV env vaccination, a limited set of rectal biopsies showed no evidence for increased Ad-specifi c T cell activation in low-risk volunteers and a different host gene activation signature from that in Ad5-vaccinated individuals ( 6) . Nonetheless, a description of the rAd5 experience should be included in informed consents associated with HIV vaccine trials using alternate Ad vectors.
It is conceivable that increased risk of HIV infection could be associated with any vaccination strategy that activates T cells, especially at mucosal surfaces. If the balance between the stimulation of protective anti-HIV responses versus Ad-specifi c responses that activate CD4 + T cells leans toward an anti-HIV response, then protection might be seen despite the presence of susceptible T cell targets. However, increased risk to infection may be seen if the anti-HIV response is weak and does not counterbalance the increased susceptibility of activated CD4 + T cells; if the anti-HIV response wanes faster than the CD4 + T cell activation; or if the Adinduced response is maintained and boosted by reexposure to alternative adenoviruses. Furthermore, cellular immune responses against Ad5, regardless of Ad serostatus, diminished anti-HIV responses to rAd5-HIV vaccination in Step ( 15) . Thus, the effi cacy of an HIV vaccine may refl ect a balance of two competing activities-anti-HIV responses and T cell activation.
Considerations for the Future
Given the increased risk and the lack of efficacy in trials using rAd5, further HIV vaccine studies testing rAd5 vectors are not appropriate. When considering HIV vaccines that are designed to elicit a component of T cell immunity, a risk-benefi t analysis should consider the balance between anti-HIV responses and vector-directed responses that activate 
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based vaccines should evaluate the amounts and distribution of both vector and insert responses in target tissues where HIV acquisition is known to occur.
Other research activities could be pursued to help clarify the roles of antivector responses in overall HIV vaccine efficacy. For example, nonhuman primate studies using empty vectors or vectors with non-HIV inserts as placebo controls could define the levels of antivector immunity and evaluate the effect on virus acquisition of this vector-related activation of CD4 + T cells independent of an anti-HIV response. Also, the fi eld could benefi t from additional nonhuman primate studies. For example, the identifi cation of biomarkers in primates that indicate increased risk of acquisition ( 18) could be valuable to monitor for risk in early-phase human studies.
A better understanding of mucosal immune responses to HIV vaccination is also needed. The timing, location, and number of mucosal biopsies that defi ne the vaccine-induced gut immune responses need clarifi cation. Understanding the infl uence of the mucosal microbiome on vaccination ( 19) and the impact specifi cally of the virome will be important. Particularly for Ad-based vectors, understanding components of risk related to the level of Ad exposure and persistence will be essential.
For non-HIV vaccine trials using vectors that induce strong T cell immunity that are conducted in regions with high HIV incidence, it may be important to monitor for HIV acquisition, depending on the target population. In such studies where the population may be at risk of HIV exposure, HIV incidence should be monitored at the end of the study and for an appropriate follow-up period.
The experience with rAd5-based HIV vaccines has shown that vaccine-induced protection likely reflects the balance between benefi cial anti-HIV responses and deleterious effects of immune activation that increases the susceptibility of CD4 + T cells to infection (see the fi gure). Among the spectrum of existing or planned vaccines, this phenomenon is likely unique for an HIV vaccine because the activated CD4 + T cell is the very target for the virus. These observations should be taken into consideration in future HIV vaccine research endeavors and underscores the importance of maximizing the specifi c anti-HIV responses of such candidates.
T he global mid-ocean ridge system is an interconnected network of volcanoes that produces the oceanic crust, which covers 70% of Earth's surface. The physical and chemical attributes of midocean ridges, such as the depth of the volcanic ridge axis below the sea surface, the thickness of the oceanic crust created there, the composition of the erupted lava, and the way seismic waves interact with the mantle beneath the ridge, collectively reflect the properties of the mantle that melts to form the oceanic crust. On page 80 of this issue, Dalton et al. ( 1) explore relationships between global seismic wave velocities in the mantle beneath mid-ocean ridges and a global data set of ridge depth and lava chemistry ( 2) . They fi nd strong correlations between these three factors, ultimately linking the trends to a global mantle temperature variation of ~250°C.
Lavas erupted at mid-ocean ridges form as the mantle moves upward in response to tectonic plate movements at the surface. As the mantle ascends, it melts at a depth controlled partly by its temperature ( 3) , such that hotter mantle will start melting deeper and produce more magma, ultimately leading to a shallower ridge axis and a thicker oceanic Graduate School of Oceanography, University of Rhode Island, Narragansett, RI 02882, USA. E-mail: kelley@gso. uri.edu
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Creating oceanic crust at mid-ocean ridges. As the mantle moves upward beneath mid-ocean ridges, it melts and creates a volcanic chain (ridge axis) that constructs the oceanic crust. (A) At cooler temperature, less melting takes place, the ridge axis is deep, and the oceanic crust is thin. (B) Higher temperatures enable more melting, creating a shallower axis and thicker crust.
